MRSN
Mersana Therapeutics Inc.
$7.35
+$0.10(+1.38%)
25
Overall
--
Value
25
Tech
--
Quality
Market Cap
$35.98M
Volume
43.05K
52W Range
$5.21 - $70.75
Target Price
$28.29
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | $17.5M | $10.6M | $42.1M | $828.0K | $43.0K | $26.6M | $36.9M | $40.5M | ||
| Total Revenue | $17.5M | $10.6M | $42.1M | $828.0K | $43.0K | $26.6M | $36.9M | $40.5M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | $17.5M | $10.6M | $42.1M | $828.0K | $43.0K | $26.6M | $36.9M | $40.5M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $-57.2M | $-76.2M | $72.3M | $88.9M | $168.9M | $230.3M | $216.5M | $113.8M | ||
| Research & Development | $46.7M | $59.9M | $55.0M | $67.0M | $132.0M | $173.4M | $148.3M | $73.0M | ||
| Research Expense | $46.7M | $59.9M | $55.0M | $67.0M | $132.0M | $173.4M | $148.3M | $73.0M | ||
| Selling, General & Administrative | $10.5M | $16.3M | $17.3M | $21.9M | $36.9M | $57.0M | $59.5M | $40.8M | ||
| General & Administrative Expenses | $10.5M | $16.3M | $17.3M | $21.9M | $36.9M | $57.0M | $59.5M | $40.8M | ||
| Salaries & Wages | $-1.4M | $-3.9M | -- | -- | -- | $21.5M | $21.1M | $16.5M | ||
| Depreciation & Amortization | $-928.0K | $-1.3M | $1.2M | $1.0M | $900.0K | $900.0K | $1.5M | $1.6M | ||
| Depreciation & Amortization | $-928.0K | $-1.3M | $1.2M | $1.0M | $900.0K | $900.0K | $1.5M | $1.6M | ||
| Amortization | -- | -- | $75.0K | $101.0K | $169.0K | $194.0K | $185.0K | $138.0K | ||
| Other Operating Expenses | $-57.2M | $-76.2M | $72.3M | $2.8M | $3.5M | $3.8M | $3.8M | $3.8M | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-39.6M | $-65.7M | $-30.2M | $-88.1M | $-168.9M | $-203.8M | $-171.0M | $-73.3M | ||
| EBITDA | $-38.1M | $-63.3M | $-27.0M | $-86.7M | $-167.9M | $-200.0M | $-170.2M | $-63.3M | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | -- | -- | $234.0K | $359.0K | $1.3M | $3.3M | $16.0K | $3.9M | ||
| Intinc | $910.0K | $1.4M | $2.2M | $424.0K | $65.0K | $2.9M | $12.1M | $8.4M | ||
| Net Non-Operating Interest Income/Expense | $910.0K | $1.4M | $2.0M | $65.0K | $-1.2M | $-445.0K | $12.1M | $8.4M | ||
| Other Income/Expense | -- | $-8.7M | $-41.6M | $-828.0K | $-43.0K | $-43.0K | $-27.9M | $-27.3M | ||
| Other Special Charges | -- | $8.7M | $41.6M | $828.0K | $43.0K | $43.0K | $27.9M | $27.3M | ||
| SPECIAL ITEMS | ||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $8.7M | -- | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $-8.7M | -- | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-38.7M | $-64.3M | $-28.0M | $-87.7M | $-168.8M | $-200.9M | $-171.7M | $-64.9M | ||
| Pre-Tax Income | $-38.7M | $-64.3M | $-28.2M | $-88.0M | $-170.1M | $-204.2M | $-171.7M | $-68.8M | ||
| INCOME TAX | ||||||||||
| Tax Provision | -- | -- | -- | -- | -- | -- | -- | $418.0K | ||
| NET INCOME | ||||||||||
| Net Income | $-38.7M | $-64.3M | $-28.2M | $-88.0M | $-170.1M | $-204.2M | $-171.7M | $-69.2M | ||
| Net Income (Continuing Operations) | $-38.7M | $-64.3M | $-28.2M | $-88.0M | $-170.1M | $-204.2M | $-171.7M | $-69.2M | ||
| Net Income (Discontinued Operations) | $-38.7M | $-64.3M | $-28.2M | $-88.0M | $-170.1M | $-204.2M | $-171.7M | $-69.2M | ||
| Net Income (Common Stockholders) | $-38.7M | $-128.5M | $-28.2M | $-88.0M | $-170.1M | $-204.2M | $-171.7M | $-69.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-68.1M | ||
| TOTALS | ||||||||||
| Total Expenses | $-57.2M | $-76.2M | $72.3M | $88.9M | $168.9M | $230.3M | $216.5M | $113.8M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $480.9K | $921.3K | $1.7M | $2.5M | $2.8M | $3.7M | $4.6M | $122.5M | ||
| Average Shares Outstanding (Diluted) | $480.8K | $921.2K | $1.7M | $2.5M | $2.8M | $3.7M | $4.6M | $122.5M | ||
| Shares Outstanding | $913.8K | $1.9M | $1.8M | $2.8M | $3.3M | $4.3M | $4.9M | $124.6M | ||
| Basic EPS | -- | -- | $-16.25 | $-35.75 | $-60.25 | $-54.5 | $-37 | $-0.56 | ||
| Basic EPS (Continuing Operations) | -- | -- | $-16.25 | $-35.75 | $-60.25 | $-54.5 | $-37 | $-0.56 | ||
| Diluted EPS | $-80.5 | $-69.75 | $-16.25 | $-35.75 | $-60.25 | $-54.5 | $-37 | $-0.56 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-60.25 | $-54.5 | $-37 | $-0.56 | ||
| OTHER METRICS | ||||||||||
| Accrued Preferred Stock Dividends | $38.7M | $64.3M | $28.2M | $88.0M | $170.1M | $204.2M | $171.7M | $69.2M | ||
| Other Gand A | $10.5M | $16.3M | $17.3M | $21.9M | $36.9M | $57.0M | $59.5M | $40.8M | ||
| Otherunder Preferred Stock Dividend | $38.7M | $64.3M | $28.2M | $88.0M | $170.1M | $204.2M | $171.7M | $69.2M | ||
| Preferred Stock Dividends | $38.7M | $64.3M | $28.2M | $88.0M | $170.1M | $204.2M | $171.7M | $69.2M | ||
| Rent And Landing Fees | $10.5M | $16.3M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | $8.7M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MRSN | $7.35 | +1.4% | 43.05K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Mersana Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW